Trial Filter

BETA

An intelligent search tool for clinical trials

Sign In
Back|NCT02432560Recruiting
Official Title

Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)

Sponsor
University of Cincinnati
Enrollment
600
Timeline
Mar 2015 → Jul 2025
About This Study

The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.

Eligibility Criteria

Inclusion Criteria

  • 1Female or male, age 18 or over
  • 2Diagnosis of LAM based on ATS/JRS criteria
  • 3Signed and dated informed consent
  • 4On chronic therapy, newly treated or may be considered for therapy with mTOR inhibitors or previously intolerant of or having failed mTOR inhibitor therapy

Exclusion Criteria

  • 1Inability to attend at least one RLD Clinic visit per year
  • 2Inability to give informed consent
  • 3Inability or unwillingness to perform pulmonary function testing

Locations

20 sites participating in this study

Emory University School of Medicine

Atlanta, Georgia 33136

Recruiting

Sirhari Veeraraghavan, MD

veeraraghavan@emory.edu

Stanford University Medical Center

Stanford, California 94305

Recruiting

Stephen Ruoss, MD

ruoss@stanford.edu650-723-6381

National Jewish Health

Denver, Colorado 80206

Recruiting

Gregory Downey, MD

gregory.downey@gmail.com303-398-1436
Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →